Population-based analysis of patients with COPD in Catalonia: a cohort study with implications for clinical management by Vela, Emili et al.
1Vela E, et al. BMJ Open 2018;8:e017283. doi:10.1136/bmjopen-2017-017283
Open Access 
Population-based analysis of patients 
with COPD in Catalonia: a cohort study 
with implications for clinical management
Emili Vela,1 Ákos Tényi,2,3 Isaac Cano,2,3 David Monterde,4 Montserrat Cleries,1 
Anna Garcia-Altes,5 Carme Hernandez,2,3 Joan Escarrabill,2,6 Josep Roca2,3
To cite: Vela E, Tényi Á, 
Cano I, et al.  Population-based 
analysis of patients with COPD 
in Catalonia: a cohort study 
with implications for clinical 
management. BMJ Open 
2018;8:e017283. doi:10.1136/
bmjopen-2017-017283
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
017283).
Received 13 April 2017
Revised 13 December 2017
Accepted 19 December 2017
1Area d’Atenció Sanitària, Servei 
Català de la Salut, Barcelona, 
Catalonia, Spain
2Hospital Clinic de Barcelona, 
Institut d’Investigacions 
Biomèdiques August Pi i Sunyer 
(IDIBAPS), Universitat de 
Barcelona, Barcelona, Spain
3Center for Biomedical Network 
Research in Respiratory 
Diseases (CIBERES), Madrid, 
Spain
4Institut Català de la Salut, 
Serveis Centrals, Catalunya, 
Spain
5Agencia de Qualitat i Avaluació 
Sanitaries de Catalunya 
(AQuAS), Catalunya, Spain
6Master Plan for Respiratory 
Diseases (PDMAR), Ministry of 
Health (Catalonia) REDISSEC, 
Health Services Research on 
Chronic Patients Network, 
Instituto de Salud Carlos III, 
Barcelona, Spain
Correspondence to
Professor Josep Roca;  
 jroca@ clinic. cat
Research
AbstrACt
background Clinical management of patients with 
chronic obstructive pulmonary disease (COPD) shows 
potential for improvement provided that patients’ 
heterogeneities are better understood. The study 
addresses the impact of comorbidities and its role in 
health risk assessment.
Objective To explore the potential of health registry 
information to enhance clinical risk assessment and 
stratification.
Design Fixed cohort study including all registered patients 
with COPD in Catalonia (Spain) (7.5 million citizens) at 31 
December 2014 with 1-year (2015) follow-up.
Methods A total of 264 830 patients with COPD diagnosis, 
based on the International Classification of Diseases (Ninth 
Revision) coding, were assessed. Performance of multiple 
logistic regression models for the six main dependent 
variables of the study: mortality, hospitalisations (patients 
with one or more admissions; all cases and COPD-
related), multiple hospitalisations (patients with at least 
two admissions; all causes and COPD-related) and users 
with high healthcare costs. Neither clinical nor forced 
spirometry data were available.
results Multimorbidity, assessed with the adjusted 
morbidity grouper, was the covariate with the highest 
impact in the predictive models, which in turn showed high 
performance measured by the C-statistics: (1) mortality 
(0.83), (2 and 3) hospitalisations (all causes: 0.77; COPD-
related: 0.81), (4 and 5) multiple hospitalisations (all 
causes: 0.80; COPD-related: 0.87) and (6) users with high 
healthcare costs (0.76). Fifteen per cent of individuals with 
highest healthcare costs to year ratio represented 59% of 
the overall costs of patients with COPD.
Conclusions The results stress the impact of assessing 
multimorbidity with the adjusted morbidity grouper on 
considered health indicators, which has implications for 
enhanced COPD staging and clinical management.
trial registration number NCT02956395.
IntrODuCtIOn 
Chronic obstructive pulmonary disease 
(COPD) is one of the major disorders 
included in the WHO programme addressing 
non-communicable diseases.1 It is estimated 
that COPD will become the third leading 
cause of death by 2020.2 Moreover, projec-
tions on COPD prevalence and costs over 
the next 15 years indicate a rapidly escalating 
burden, mainly due to population ageing, on 
both health and social support systems.3 4 
While acknowledging the progress made in 
terms of standard of care recommendations,5 
it is accepted that a better understanding of 
patients’ heterogeneities constitutes a key 
challenge to further enhance both preven-
tion and management of patients with 
COPD aiming at healthcare value genera-
tion.6 7 Recent studies indicate a high impact of 
comorbidities on use of healthcare resources 
in patients with COPD prompting the need 
for assessing novel integrated care strategies 
with a patient-oriented approach.8 9 It is well 
accepted that several prevalent chronic condi-
tions often occur as clusters of comorbidities 
in patients with COPD10–12 and potential 
explanatory mechanisms for the phenom-
enon have been proposed.13 14
The current study addresses comorbidities 
in patients with COPD based on the hypoth-
esis that assessment of all patients with COPD 
living in a given geographical area, a popu-
lation-based analysis of the patients with 
the disease, can provide valuable insights 
strengths and limitations of this study
 ► The main strength of the study is that it contributes 
to risk prediction of relevant clinical events in 
patients with chronic obstructive pulmonary disease 
(COPD).
 ► The study shows high potential to assess health 
risk factors at population level indicating the high 
impact of comorbidities. It can contribute to define 
innovative strategies aiming at reducing the 
healthcare impact of patients with COPD.
 ► Full potential of the approach should be proven 
by integrating registry information and electronic 
medical records.
 ► Lack of clinical information, spirometric data and 
history of tobacco smoking reduces the potential for 
standardised risk characterisation of patients with 
COPD.
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to better understand COPD heterogeneity. Specifically, 
the research objective was to explore the potential of 
the health registry information contained in the Health 
Surveillance System of the region of Catalonia (Spain) 
(7.5 million inhabitants) to enhance health risk assess-
ment and stratification in the clinical arena.15 16 To this 
end, we analysed a total of 264 830 patients with COPD 
from all healthcare layers, registered in 31 December 2014 
and followed up in 2015, to elaborate predictive models 
for six key health indicators: (1) mortality, (2 and 3) 
hospitalisations (all causes and COPD-related), (4 and 5) 
multiple hospitalisations (all causes and COPD-related) 
and (6) users with high healthcare costs. Ultimately, this 
study aimed to consider the weight of the different covari-
ates included in the predictive models to provide useful 
information to enhance clinical management.
The study is a relevant component of the programme 
for collaborative management of complex chronic 
patients being deployed in the region during the period 
2016–2020.17 An ancillary aim of the research was to assess 
factors determining the economic impact of the patients 
with the disease, as well as to identify areas of action to 
increase healthcare efficiencies in the management of 
these patients.
MethODs
Population-based risk assessment: adjusted morbidity 
grouper
The Catalan Health Surveillance System (CHSS) includes 
updated registries of the region of Catalonia (Spain) 
(7.5 million inhabitants) from Primary Care, Hospital-re-
lated events (hospitalisations, emergency room consulta-
tions and specialised outpatient visits), Pharmacy, Mental 
Health, Socio-sanitary services and other items (home-
based respiratory therapies, dialysis, outpatient rehabil-
itation and non-urgent healthcare transportation) since 
2011.18 19 It allows analyses on use of healthcare resources, 
pharmacy consumption, prevalence of key disorders and 
population-based health risk assessment.15 16 It is of note 
that although integration of CHSS registry data with elec-
tronic medical records is not yet in place, it constitutes 
the main goal of the PADRIS programme,20 officially 
launched on January 2017.
The regional population-based health risk assessment 
tool, named GMA (Adjusted Morbidity Groups), is used 
to elaborate the health risk strata pyramid of the general 
population of Catalonia (figure 1, left triangle).15 16 The 
GMA tool predicts individual patient risk, periodically 
updated on a 6-month basis, based on multimorbidity 
information gathered from CHSS registry data. The ratio-
nale behind the use of GMA, against alternative health 
risk assessment tools, is that it complies with four main 
recommended criteria,15 that is, (1) a population health 
approach (uses the entire population of 7.5 million 
inhabitants of the region), (2) publicly owned without 
licensing constraints, (3) open source computational 
algorithms and (4) the adjusted morbidity grouper relies 
mostly on statistical criteria, as opposed to other tools that 
include expert-based coefficients, thus facilitating quick 
transferability to other territories. Detailed descriptions 
of the GMA, as well as its evaluation, have been reported 
elsewhere.15 16 Methodological details of the GMA algo-
rithm are described in the online supplementary figure 
1S.
study dataset and design
The current study design is a fixed cohort analysis of the 
entire population of 264 830 patients, alive and above 
39 years of age, included in the CHSS on 31 December 
2014 with the clinical diagnosis of COPD. New patients 
registered during 2015 were not included in the study. 
For the study purposes, the diagnosis of COPD was based 
on the International Classification of Diseases (Ninth 
Edition) coding21 (online supplementary table 1S) 
declared by the patient’s responsible physician, either a 
Figure 1 GMA health risk grades. The left triangle depicts the distribution of all Catalan citizens, expressed as percentage, 
in five arbitrary health risk layers defined using the GMA (Adjusted Morbidity Groups)15 16 as a population-based health risk 
stratification tool. The central triangle indicates the distribution in these five health risk layers of the subset of Catalan citizens 
older than 39 years. The right triangle displays the distribution of the study group of patients with chronic obstructive pulmonary 
disease (COPD) (264 830 patients) across the GMA health risk grades: baseline, low, moderate, high and very high.
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primary care professional or a specialist. The study did 
not take into account background clinical information, 
nor forced spirometry data.
The analyses were carried out for the entire population 
of patients with COPD, but the study considered different 
subsets of patients based on the GMA health risk grading: 
(1) baseline, (2) low, (3) moderate, (4) high and (5) very-
high-risk patients. The thresholds defining these subsets 
of patients correspond to the percentiles 50, 80, 95 and 99 
of the GMA grading for the general population (figure 1, 
left triangle). For the purposes of the study, patients with 
COPD falling into the baseline health risk group (1%) 
were merged with the low-risk group such that only four 
GMA grades were considered in the analysis (figure 1, 
right triangle).
Health risk predictive modelling was elaborated with 
registry data from year 2015 for the six main dependent 
variables: (1) mortality, (2 and 3) hospitalisation (all 
causes and COPD-related), (4 and 5) multiple hospital-
isations (all causes and COPD-related) and (6) users with 
high healthcare costs, as described below. In the study, 
dependent variables were defined as binary variables. 
Mortality was defined as true if a patient died during the 
period from 1 January to 31 December 2015, regardless 
of whether it occurred in the hospital, at the patient’s 
home or in other settings such as skilled nursing facili-
ties. The category all causes hospitalisations was true if a 
patient had one or more hospital admissions due to any 
cause during 2015. COPD-related hospitalisations refer 
only to events triggered by acute exacerbations of COPD. 
Multiple hospitalisations were defined as two or more 
hospital admissions. Users with high healthcare costs 
refer to subjects above percentile 85 (PCT85) in terms of 
yearly healthcare costs during 2015.
The study used retrospective deidentified data from 
administrative databases (CHSS). Therefore, neither 
informed consent nor ethical committee approval was 
required according to the current legislation in Catal-
onia. The analyses were developed under the umbrella 
of the Nextcare project (http://www. nextcarecat. cat/) 
(https:// clinicaltrials. gov/: NCT02956395).
Assessment of economic burden
Allocation of healthcare expenditure to each patient, 
including pharmacy, was done through the Personal 
Health Identification Number since it allows each billing 
invoice to be attributed to a given patient. The health-
care expenditure includes hospitalisation, primary care, 
pharmacy, health transport, respiratory home care ther-
apies, outpatient visits and skilled nursing facilities. The 
key outcome variable of the analysis was 1-year healthcare 
resource use and expenditure by patient.19 Calculation of 
individual healthcare costs was done by addition of costs 
for each item included in the CHSS registries alluded to 
above. This methodology allows calculation of the total 
healthcare expenditure in patients with COPD. Conse-
quently, it allows to perform a holistic analysis of health-
care expenditure.
statistical analysis
The study outcomes are described for the entire popula-
tion of patients with COPD. Comparisons among the four 
subgroups defined by GMA health risk grades were done. 
The results are summarised in the main manuscript and 
complementary information is reported in detail in the 
online supplementary material. In this population-based 
analysis (table 1), age and number of chronic comor-
bidities are summarised as mean and SD, the propor-
tion of women and the morbidities are expressed as 
percentages, while mortality rate, hospitalisation rate and 
COPD-related hospitalisation rate are expressed per 100 
patients with COPD among patient groups. Comparisons 
among groups were done using analysis of variance for 
continuous variables, and χ2 test for binary and nominal 
variables.
Statistical analyses were performed using SPSS soft-
ware V.18.0. All statistical tests and confidence intervals 
were constructed with a type I error (alpha) level of 5%, 
and P values lower than 0.05 were considered statistically 
significant.
Predictive modelling
Multiple logistic regression analyses were used to generate 
health risk predictive models for the six main outcome 
variables of the study, namely, (1) mortality, (2 and 3) 
hospitalisation (all causes and COPD-related), (4 and 5) 
multiple hospitalisations (all causes and COPD-related) 
and (6) users with high healthcare costs. The following 
model independent variables were considered: age, sex, 
GMA health risk grades, previous history of hospital 
admissions, emergency room consultations and use of 
social support services. Each independent variable was 
included in the model as a categorical variable to allow 
for possible non-linearity in the relationship between vari-
ables and the relevant outcomes. For each measure, we 
collapsed the uppermost categories to ensure there were 
enough individuals in each cell to allow estimation of 
the parameters. All covariates were entered in the model 
one by one and retained when they showed a signifi-
cant contribution to the predictive accuracy (P<0.10). 
The predictive role of each covariate into the model was 
assessed with a log-likelihood ratio test. To evaluate the 
performance of the resulting predictive models, we calcu-
lated the C-statistics (ie, the area under the receiver oper-
ating characteristic curve).22 23
results
Population-based analysis
The distribution of the entire population of the region in 
the health risk strata pyramid is depicted in figure 1, left 
triangle, wherein citizens are distributed in five health risk 
grades defined by the GMA percentiles, namely, (1) 50% 
of the population with baseline health risk (green), (2) 
30% of individuals with low health risk (yellow), (3) 15% 
with moderate health risk (orange), (4) four percent with 
high risk and (5) 1% with very high health risk (brown). 
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These risk strata show strong associations with mortality, 
hospital admissions, use of healthcare resources and 
expenditures, as reported in detail elsewhere.15 16
The central triangle (figure 1) indicates the distribu-
tion of the general population older than 39 years in 
the five health risk grades, described above. It consti-
tutes the reference risk strata pyramid to be compared 
with the population-based COPD analysis. Finally, the 
distribution of the study group of patients with COPD is 
depicted in the right triangle that indicates the effects of 
the chronic pulmonary disease on health risk stratifica-
tion. As expected, most of the patients with COPD (84%) 
were distributed between moderate (46%), high (29%) 
and very high (9%) health risk layers. Only 15% of the 
patients fell in the low risk level (yellow) and 1% were 
allocated in the baseline health risk level (green).
The study showed a COPD prevalence of 6.6% of all 
subjects above 39 years of age. The mean age was 70 
(SD 12.5) years. Women represented 36% of the study 
group. On average, these patients presented 5.6 (SD 2.1) 
comorbid conditions. The mortality rate was 6.2%. The 
hospitalisation rate, all causes, was 17.4% (n=46 149), 
whereas the rate of COPD-related hospitalisations was 
4.3% (n=11 470), which represents 24.9% of the total 
number of hospitalisations registered in these patients. As 
expected, the rate of comorbidities showed a consistent 
increase with GMA grading, which was the most apparent 
for cardiovascular disorders, type 2 diabetes mellitus–
metabolic syndrome and/or anxiety–depression, as 
displayed in table 1.
Predictive modelling
The summary information of the predictive modelling 
for each of the six outcome variables—mortality, hospi-
talisations (all causes and COPD-related hospitalisations), 
multiple hospitalisations (all causes and COPD-related 
Table 1 Main characteristics of the study group by GMA health risk grades
Low risk Moderate risk High risk Very high risk Total
Patients (n) 41 809 121 918 76 237 24 866 264 830
Age (years)* 60.8±11.8 69.4±11.8 75.1±10.9 77.4±10.1 70.5±12.5
Women (%)* 36.0 36.2 35.9 35.3 36.0
Morbidity
  No of chronic comorbidities* 2.9±1.1 5.2±1.4 7.0±1.6 8.4±1.7 5.6±2.1
  Diabetes (%)* 5.2 22.7 39.4 52.6 27.5
  Heart failure (%)* 0.2 5.2 30.7 63.7 17.2
  Hypertension (%)* 24.0 60.4 81.1 88.9 63.3
  Renal failure (%)* 0.3 5.8 23.4 47.8 13.9
  Dementia (%)* 0.3 2.6 7.8 13.6 4.7
  Cirrhosis (%) 0.5 1.6 3.0 4.8 2.1
  Depression (%) 8.8 20.1 28.6 34.2 22.1
  Stroke (%)* 0.5 5.9 19.2 31.8 11.3
  Ischaemic coronary disease (%)* 0.9 9.0 28.0 42.7 16.4
  Malignancy (%)* 4.2 17.0 32.1 40.9 21.6
  Locomotor system (%)* 29.3 56.3 67.9 72.0 56.8
  Osteoporosis (%)* 3.9 10.0 14.3 17.9 11.0
  Arthrosis (%)* 9.8 32.8 47.6 51.0 35.1
2015 events n (%) n (%) n (%) n (%) n (%)
  Mortality* 391 (0.9) 3213 (2.6) 6792 (8.9) 5955 (23.9) 16 351 (6.2)
  Patients with hospitalisations (all causes)* 1785 (4.3) 12 451 (10.2) 19 417 (25.5) 12 496 (50.3) 46 149 (17.4)
  Patients with hospitalisations (COPD 
related)*
404 (1.0) 2769 (2.3) 4697 (6.2) 3600 (14.5) 11 470 (4.3)
  Patients with multiple hospitalisations (all 
causes)*
366 (0.9) 3026 (2.5) 6687 (8.8) 6035 (24. 0) 16 114 (6.1)
  Patients with multiple hospitalisations 
(COPD related)*
71 (0.2) 524 (0.4) 1169 (1.5) 1210 (4.9) 2974 (1.1)
  Users with high healthcare costs* 1119 (2.7) 10 064 (8.3) 17 333 (22.7) 11 609 (46.7) 40 125 (15.2)
Age and number of chronic comorbidities expressed as mean±SD; gender and morbidities are expressed as percentages; comparisons 
among risk grades were done using analysis of variance for continuous variables and χ2 test for binary and nominal variables.
*P<0.01.
COPD, chronic obstructive pulmonary disease; GMA, Adjusted Morbidity Groups.
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repeated admissions) and users with high healthcare 
costs—are depicted in table 2, wherein significant covari-
ates, the corresponding ORs and the C-statistics are indi-
cated for each predictive model.
It is of note that age, closely followed by GMA grading, 
showed the two highest independent associations in the 
mortality model. Likewise, GMA grading depicted the 
highest predictive role in three out of the six models: 
hospitalisations (all causes), multiple hospitalisations (all 
causes) and users with high healthcare costs. Interestingly, 
for COPD-related events (hospitalisations and multiple 
hospitalisations), the covariate with highest predictive 
role was history of hospitalisations, whereas the ORs of 
the covariate GMA grades were markedly lower than in 
the other predictive models.
economic impact of patients with COPD
Figure 2 compares the costs of the different items, 
expressed as percentages, for the general population of 
Catalonia (outer circle) and those generated by the study 
Table 2 Summary description of the six predictive models
Mortality
Hospitalisations Multiple hospitalisations Users with high healthcare 
costs (PCT85)All causes COPD related All causes COPD related
C-statistics (AUC) 0.829 0.766 0.807 0.803 0.865 0.763
Covariates OR
Sex
  Male 1 1 1 1 1 1
  Female 0.701 0.825 0.885 0.818 0.823 0.84
Age (years)
  40–54 1 1 1 1 1 1
  55–64 1.693 1.254 1.435 1.308 1.428 0.884
  65–74 2.103 1.506 1.675 1.576 1.7 0.91
  75–84 3.749 2.054 2.017 1.983 1.634 0.898
  >84 9.911 2.827 2.049 2.335 1.272 0.681
Admissions
  Group A 1 1 1 1 1 1
  Group B 1.394 1.903 4.699 1.952 6.952 1.59
  Group C 1.368 2.039 8.592 2.266 15.214 1.577
GMA grade
  Low 1 1 1 1 1 1
  Moderate 1.826 1.896 1.644 2.128 1.649 3.125
  High 4.316 3.998 2.646 5.419 2.852 8.858
  Very high 8.919 7.851 3.548 11.042 3.891 20.285
Emergency room visits
  0 1 1 1 1 1 1
  1–2 1.106 1.405 1.37 1.526 1.505 1.353
  3–5 1.276 1.865 1.684 2.179 2.013 1.771
  >5 1.643 2.615 2.235 3.354 3.032 2.428
Social support
  No 1 1 1 1 1 1
  Yes 2.289 1.008 0.892 0.917 0.922 0.877
The intensities of grey background colour reflect the magnitude of ORs, being white when value is one and stronger grey when they are closer 
to 0 or have a higher positive value.
Admissions:
Group A corresponds to patients with no registries of hospital admissions within the period 2011–2014; Group B includes patients with history 
of admissions before 2014, but without admissions in that year; Group C includes patients with hospital admissions during 2014. Graphical 
representation and details of the six predictive models with the corresponding 95% CIs of the ORs are shown in the online supplementary 
figures 2S–7S and tables 2S–7S.
AUC, area under the receiver operating characteristic curve; COPD, chronic obstructive pulmonary disease; GMA, Adjusted Morbidity 
Groups.
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group of patients with COPD (inner circle). Briefly, COPD 
hospitalisations, pharmacy, skilled nursing care and other 
costs (respiratory therapies) are above the mean cost of 
the corresponding items in the general population of the 
region.
The average healthcare costs of patients with COPD 
per year was €4238 as compared with a mean of €987 
a year per citizen in the region. It is of note that the cost 
generated by patients with COPD represents 13.5% of the 
overall healthcare costs in the region.
The cost analysis by GMA grading (figure 3) clearly 
showed a steady increase of costs per patient/year 
with considered GMA risk grades: (1) low, €1284; (2) 
moderate, €2944; (3) high, €5933; and (4) very high, 
€11 537. Hospitalisation and pharmacy are the two items 
with highest impact on costs associated to GMA grading. 
It is worth to mention that we observed huge differences 
(7.41 times) between the users with high healthcare costs 
per year (PCT85: €16 131), which represents 59% of the 
overall costs of patients with COPD, and patients with 
COPD below PCT85 (€2177). Online supplementary table 
8S indicates use of healthcare resources by GMA category.
DIsCussIOn
Interpretation of the main findings
The main finding of the current study was the identifica-
tion of comorbidities, expressed as GMA grades, as the 
covariate with highest discriminative impact on target 
events (mortality, hospitalisations) (table 2) and on yearly 
healthcare costs per patient (figure 3). These results can 
be relevant for commissioning of innovative healthcare 
services aiming at preventing materialisation of recent 
predictions on increases of healthcare impact of patients 
with COPD over the next 15 years.3 4 However, they may 
also foster enhanced clinical management of individual 
cases with COPD.
It is of note that the performance of these models 
(table 2 and online supplementary figure S2–S7) shows 
quite acceptable goodness of fit (ie, C-statistics), indi-
cating the potential of exploring synergies between popu-
lation-health risk assessment (ie, GMA grading system) 
and clinical information to enhance health risk assess-
ment and stratification in the clinical arena, as reported 
in Dueñas-Espín et al.15 Ultimately, integration between 
registry data and electronic medical records of healthcare 
providers emerge as a high priority goal to properly pave 
the way towards personalised medicine for patients with 
chronic disorders.24
As expected, the covariate GMA showed a higher contri-
bution in all causes hospital-related events than in only 
COPD-related admissions (table 2). It is of note that the 
latter represented only 22% of all admissions (table 1). 
While current GOLD recommendations address pulmo-
nary events explaining frequent COPD exacerbations, the 
results of the current study suggest the need for further 
analyses aiming at identifying specific management 
needs for complex patients with COPD and comorbid 
conditions.
two complementary healthcare strategies
The distribution of patients with COPD in the regional 
health risk stratification pyramid (figure 1, right triangle) 
allows identification of two different scenarios with 
well-defined associated challenges.
Patients with high health risk
The distribution of yearly healthcare costs per patient 
(figure 3) provides a strong rationale for targeting 
Figure 2 Indicates the distribution of costs of main items, 
expressed as percentages. The outer circle corresponds to 
overall cost for the Catalan Health System, whereas the inner 
circle indicates the corresponding relative costs ascribed to 
patients with chronic obstructive pulmonary disease (COPD). 
The absolute values are (1) Hospitalisation (€2291.8 million 
and €356.6 million, respectively), (2) Pharmacy (€2193.4 
million and €325.8 million), (3) Primary care (€1745.0 million 
and €158.9 million), (4) Outpatient specialised care (€842.9 
million and €98.1 million), (5) Emergency department (€401.5 
million and €29.7 million), (6) Skilled nursing facility (Catalonia 
€155.1 million; COPD €37.5 million), and (7) Other (€404.0 
million and €78.0 million). The last item, Others, includes 
home-based respiratory therapies, dialysis, outpatient 
rehabilitation and non-urgent healthcare transportation.
Figure 3 Average patient cost per year and relative 
contribution of the seven items (see text and figure 2 legend) 
for the four subgroups of patients with chronic obstructive 
pulmonary disease classified according to the GMA (Adjusted 
Morbidity Groups) scoring from low health risk (left column) to 
very high health risk (right column).
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patients close to the tip of the risk stratification pyramid 
as candidates for large-scale deployment of innovative 
services based on care coordination. However, two main 
limiting factors should be overcome in order to achieve 
proper designs of integrated care services.25 First, poor 
comparability among interventions assessing effects on 
integrated care management for patients with COPD 
indicates an urgent need for standardisation of service 
workflows. Second is the limited healthcare impact of 
standard interventions addressed to patients at the tip of 
the pyramid,26 that is, the low ratio between magnitude 
of the interventional effects and the resources devoted 
to achieve them, which may imply little healthcare value 
generation.6 7 These two factors strengthen the need for 
further evidence on cost-effectiveness of well-defined inte-
grated care interventions for complex chronic patients.27
Patients with low and moderate health risk
A better understanding of underlying mechanisms of 
comorbidity clustering in these patients emerges as a 
central need to effectively slow down patients’ progress 
towards the tip of the pyramid. A natural consequence 
should be the development of efficient preventive inter-
ventions28 aiming at delaying patients’ worsening in terms 
of health risk scoring, which is recognised as a central 
unmet need for enhanced COPD management.
strengths and limitations of the study
The uniqueness of the current study is that it was carried 
out using registry data that allow population-based anal-
yses of all patients with a given condition(s) in the region. 
It is of note that complexities involved in implementation 
and optimisation of large-scale health information tech-
nology systems often impede health assessment of the 
entire population in a real-world setting.29
We acknowledge, however, that the use of registry infor-
mation alone reflects underdiagnosis of COPD and consti-
tutes a significant limitation that may explain a rather low 
figure for COPD prevalence in the region.5 30 The lack 
of clinical information, spirometric data and history of 
tobacco smoking reduces the potential for a proper char-
acterisation of patients with COPD. As indicated above, 
the barriers associated to the existence of health informa-
tion silos further strengthens the need for speeding up 
the current efforts to achieve real integration between 
clinical and registry data5 that will open new avenues to 
enhance both medical knowledge and clinical practice.
Episodes of inpatient and outpatient care carried out 
in private hospitals were not available for analysis because 
private providers do not use the Personal Health Identifi-
cation Number. Nevertheless, the vast majority (approxi-
mately 97.5% in 2015) of COPD hospitalisations are done 
in public hospitals.
Clinical impact and perspectives generated by the study
The current study confirms that prevalent chronic condi-
tions such as cardiovascular disorders, type 2 diabetes 
mellitus–metabolic syndrome and/or anxiety-depression 
often occur in high-risk patients with COPD.10–12 We 
believe that the study provides a strong rationale for 
further research on subject-specific health risk prediction 
and stratification aiming at early identification of patients 
with low to moderate health risk who are prone to develop 
comorbid conditions in order to enhance preventive 
management in a cost-effective manner.31 32 The current 
research may contribute to foster future developments 
of GOLD recommendations5 addressing non-pulmo-
nary manifestations of COPD that should have a positive 
impact on both staging and management of complex 
chronic patients.
Moreover, the study reinforces the ongoing strategies 
aiming at speeding up the evolution of the current health 
surveillance system in Catalonia towards a Digital Health 
Framework conceptually formulated in Cano et al33 34 
with potential to articulate three categories of data: (1) 
outcomes from population-based health-risk predictive 
models; (2) healthcare and biomedical research knowl-
edge resulting from integration of clinical, physiolog-
ical and biological/molecular information; and (3) 
informal care information from in-place personal health 
folders15 17 encompassing information on lifestyle, adher-
ence profile, socioeconomic status, social support and 
environmental factors. It is envisaged that inclusion of 
all these covariates influencing patient health should 
markedly increase the predictive accuracy and facilitate 
clinical decision-making based on sound estimates of the 
prognosis of an individual.
COnClusIOns
The current study provides a population-based analysis 
of 264 830 patients with COPD based on administra-
tive health registries in Catalonia. The results illustrate 
the high impact of comorbidities on undesirable clin-
ical events. We believe that the results highly encourage 
further developments fostering interoperability between 
health registries and electronic medical records to 
enhance clinical risk prediction.
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